RCEL
RCEL
NASDAQ · Biotechnology

Avita Medical Inc

$4.13
-0.12 (-2.82%)
As of Jun 30, 10:31 PM ET ·
Financial Highlights (FY 2026)
Revenue
77.72M
Net Income
-52,729,862
Gross Margin
83.3%
Profit Margin
-67.9%
Rev Growth
+27.7%
D/E Ratio
9.39
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 83.3% 83.3% 48.8% 48.8%
Operating Margin -59.4% -53.5% -12.4% -14.4%
Profit Margin -67.9% -64.5% -9.8% -12.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 77.72M 60.88M 25.19M 23.71M
Gross Profit 64.71M 50.69M 12.30M 11.58M
Operating Income -46,164,200 -32,545,652 -3,131,948 -3,413,299
Net Income -52,729,862 -37,174,428 -2,467,246 -2,847,172
Gross Margin 83.3% 83.3% 48.8% 48.8%
Operating Margin -59.4% -53.5% -12.4% -14.4%
Profit Margin -67.9% -64.5% -9.8% -12.0%
Rev Growth +27.7% +27.7% +20.8% +14.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 54.52M 54.52M 29.07M 27.04M
Total Equity 5.81M 5.81M 72.39M 66.00M
D/E Ratio 9.39 9.39 0.40 0.41
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -43,613,483 -32,455,592 -4,050,890 -3,804,791
Free Cash Flow -1,532,934 -2,480,233